California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Italy Fines Apple €98.6 Million Over App Store Dominance 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
(4) - EconoTimes)
EDEN PRAIRIE, Minn., July 28, 2017 -- CHF Solutions, Inc. (NASDAQ:CHFS), today announced that on July 25, 2017, the Compensation Committee of the Board of Directors approved two equity awards under CHF Solution’s New-Hire Equity Incentive Plan, as material inducements to two individuals entering into employment with the Company. The equity awards were approved in accordance with NASDAQ Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan.
In connection with entering into employment with CHF Solutions, the two individuals, who were not previously employees or directors of CHF Solutions, received options to purchase an aggregate of 17,500 shares of the Company’s common stock. The option awards have an exercise price of $0.70 per share, the closing price of CHF Solution’s common stock on July 25, 2017, the date of the grant. The options have ten-year terms and vest over a period of four years, with 25% vesting one year after the date of grant and the remaining 75% vesting in 36 approximately equal monthly increments, provided the new hire’s employment is continuing on each such date, and subject to acceleration or forfeiture upon the occurrence of certain events as set forth in the new hire’s option agreement.
About CHF Solutions
CHF Solutions, Inc. (NASDAQ:CHFS) is an early-stage medical device company focused on commercializing the Aquadex FlexFlow system for Aquapheresis® therapy. The Aquadex FlexFlow system, is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company's objective is to improve the quality of life for patients with heart failure and related conditions. CHF Solutions is a Delaware corporation headquartered in Minneapolis with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the NASDAQ Capital Market since February 2012.
For further information, please contact: Claudia Napal Drayton Chief Financial Officer CHF Solutions, Inc. T: +1-952-345-4205 Investor Relations CHF Solutions, Inc. [email protected] -or- Bret Shapiro Managing Partner CORE IR 516 222 2560 [email protected] www.coreir.com
